Combining Lipolytics with Other Aesthetic Treatments: Protocols and Sequencing
Injectable lipolytics produce permanent fat cell destruction in the treated zone — a genuine and valued clinical result. But in the vast majority of patients, fat reduction alone does not address the full picture of their concern. The neck that carries submental fat also typically has some degree of skin laxity and platysma banding. The inner thighs with localised fat often have a surface cellulite texture component. The abdomen after fat reduction may reveal skin laxity that was previously masked by the fat volume. In each of these situations, the lipolytic component treats one dimension while other treatments address the rest.
Korean Lipolytic Products: A Practitioner's Guide to Selection and Use
Korean manufacturers have been producing pharmaceutical-grade lipolytic injectables for over two decades — longer than any other national market. The Korean aesthetic market's high volume, regulatory rigour, and clinical experimentation across multiple applications have produced a depth of lipolytic product knowledge embedded in Korean formulations that European manufacturers have not yet matched. For UK and EU practitioners, this translates to a choice of CE-marked, MFDS-approved DCA and PC/DCA products that offer pharmaceutical-grade quality at 30–50% lower wholesale cost than European alternatives.
DCA vs PC/DCA: Choosing the Right Lipolytic Agent for Your Patient
Two agents dominate injectable lipolytic practice: deoxycholic acid (DCA) as a single agent, and phosphatidylcholine combined with deoxycholic acid (PC/DCA) as a combination formulation. Both destroy subcutaneous fat cells, both produce the inflammatory clearance response that delivers the result, and both are available as CE-marked Korean formulations at Celmade. But they are not identical — and practitioners who understand the specific differences between them are better positioned to choose the right product for each clinical situation.
Lipolytic Body Contouring: Off-Label Applications for Aesthetic Practitioners
The submental zone is the best-evidenced and most widely discussed lipolytic application — but it is far from the only one. In international aesthetic practice, particularly in the Korean market where lipolytic treatments have been administered at high volume for over two decades, injectable lipolytics are used routinely across multiple body zones to address localised fat deposits that patients find resistant to diet and exercise and that significantly affect their confidence and comfort.
Submental Fat Reduction with Injectables: Patient Selection and Injection Protocol
Submental fat reduction — the non-surgical treatment of the area beneath the chin that patients refer to as a 'double chin' — is the most evidence-supported, most precisely understood, and most widely practised injectable lipolytic application in aesthetic medicine. The zone has a defined fat compartment with reasonably predictable anatomy, a pharmaceutical-grade active agent with multiple Phase 3 RCTs behind it (deoxycholic acid, branded as Kybella/Belkyra), and a well-characterised safety profile built from extensive clinical experience.
Lipolytic Injectables: The Complete Practitioner's Guide
Injectable lipolytics — agents that chemically destroy subcutaneous fat cells — represent one of the most technically specific and outcome-dependent treatments in non-surgical aesthetic medicine. When patient selection is correct, the treatment zone is appropriate, the product and protocol are sound, and the patient's expectations are accurately set, injectable lipolytics produce permanent, visible, and highly valued results. When any of these elements is wrong, the risk of adverse outcomes — prolonged swelling, irregular contour, nerve injury — increases substantially.
